SCHEMBL19453003

SCHEMBL19453003

N=C(N)c1ccc(Nc2ccc(-c3cc4ccc(C(=N)N)cc4[nH]3)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 1.00
PRMT3 O60678 1/20 1.00
CARM1 Q86X55 1/20 1.00
EHMT2 Q96KQ7 1/20 1.00
PRMT6 Q96LA8 1/20 1.00
PRMT1 Q99873 1/20 1.00
WDR77 Q9BQA1 1/20 1.00
PRMT8 Q9NR22 1/20 1.00
PRMT7 Q9NVM4 1/20 1.00
F2 P00734 2/20 0.55
ASIC3 Q9UHC3 2/20 0.49
F10 P00742 1/20 0.47
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
PRSS1 P07477 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29625896 1.00 PRMT5 (1.00) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL28176609 0.91 PRMT5 (0.83) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL235865 0.91 PRMT5 (0.83) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL29350295 0.91 PRMT5 (0.83) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL2464378 0.90 PRMT5 (0.81) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL94350 0.90 PRMT5 (0.81) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL29428907 0.90 PRMT5 (0.81) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL30442885 0.90 PRMT5 (0.81) PRMT5PRMT3CARM1EHMT2PRMT6
SCHEMBL14854556 0.90 PRMT5 (0.81) PRMT5PRMT3CARM1EHMT2PRMT6
Dapi SCHEMBL1609032 0.88 PRMT5 (0.79) PRMT5PRMT3CARM1EHMT2PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10465196-B2 Treatment of C9FTD/ALS by targeting RNA expanded repeat sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2019-11-05 US disclosed
US-20170292129-A1 TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES THE SCRIPPS RESEARCH INSTITUTE (US) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170292129-A1 TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES FUS, RAN, TARDBP PRMT5 1627/4885PRMT3 943/4885CARM1 1387/4885
US-10465196-B2 Treatment of C9FTD/ALS by targeting RNA expanded repeat sequences FUS, RAN, TARDBP PRMT5 1666/4885PRMT3 980/4885CARM1 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.